News for 89bio, Inc. (ETNB)

Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.

89bio Inc (ETNB), a clinical-stage biopharmaceutical company, announced its participation in the upcoming Leerink Partners Global Healthcare Conference on March

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the ”œCompany” or ”œ89bio”) ( ETNB), a clinical-stage biopharmaceutical company focused o

**media[556083]**

89bio Inc's innovative approach to liver and cardio-metabolic diseases positions it at the forefront of biopharmaceutical development.Despite being in the clin

On February 27, 2025, 89bio Inc (ETNB), a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ending

”“ ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associ

The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Significant Transaction on December 31, 2024 On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a notable transaction involving 89b

On January 31, 2025, JANUS HENDERSON GROUP PLC (Trades, Portfolio), a prominent investment firm, expanded its stake in 89bio Inc by acquiring an additional 5,09

On February 6, 2025, 89bio Inc (ETNB), a clinical-stage biopharmaceutical company based in San Francisco, announced the approval of non-qualified stock options

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the ”œCompany” or ”œ89bio”) ( ETNB), a clinical-stage biopharmaceutical company focused on

Ken Griffin’s Multistrategy Hedge Fund At Citadel Rose 1.

The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

On February 3, 2025, 89bio Inc (ETNB), a clinical-stage biopharmaceutical company, announced the successful closure of its underwritten public offering, raising

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (”œ89bio”) ( ETNB), a clinical-stage biopharmaceutical company focused on the development and

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of Dada Nexus Limited DADA rose sharply during Monday's session afte...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 600 points on Monday. Following the market opening Monday, the Dow traded down 0....